カレントテラピー　33-11　サンプル page 26/32

このページは カレントテラピー　33-11　サンプル の電子ブックに掲載されている26ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　33-11　サンプル

72 Current Therapy 2015 Vol.33 No.111122参考文献1） NAUTS HC, SWIFT WE, COLEY BL：The treatment ofmalignant tumors by bacterial toxins as developed by thelate William B. Coley, M.D., reviewed in the light of modernresearch. Cancer Res 6：205-216, 19462） Dranoff G：Cytokines in cancer pathogenesis and cancertherapy. Nat Rev Cancer 4：11-22, 20043） Yang J, Zhang Q, Li K, et al：Composite peptide?based vaccinesfor cancer immunotherapy（Review）. Int J Mol Med35：17-23, 20154） Krummel MF, Allison JP：CD28 and CTLA-4 have opposingeffects on the response of T cells to stimulation. J Exp Med182：459-465, 19955） Sanmamed MF, Chen L：Inducible expression of B7-H1（PD-L1）and its selective role in tumor site immune modulation.Cancer J 20：256-261, 20146） Okazaki T, Chikuma S, Iwai Y, et al：A rheostat for immuneresponses：the unique properties of PD-1 and their advantagesfor clinical application. Nat Immunol 14：1212-1218,20137） Muenst S, Schaerli AR, Gao F, et al：Expression of programmeddeath ligand 1（PD-L1）is associated with poorprognosis in human breast cancer. Breast Cancer Res Treat146：15-24, 20148） Zhang Y, Wang L, Li Y, et al：Protein expression of programmeddeath 1 ligand 1 and ligand 2 independently predictpoor prognosis in surgically resected lung adenocarcinoma.Onco Targets Ther 7：567-573, 20149） Llosa NJ, Cruise M, Tam A, et al：The vigorous immunemicroenvironment of microsatellite instable colon cancer isbalanced by multiple counter-inhibitory checkpoints. CancerDiscov 5：43-51, 201510） Pardoll DM：The blockade of immune checkpoints in cancerimmunotherapy. Nat Rev Cancer 12：252-264, 201211） Okazaki T, Chikuma S, Iwai Y, et al：A rheostat for immuneresponses：the unique properties of PD-1 and their advantagesfor clinical application. Nat Immunol 14：1212-1218,201312）Topalian SL, Sznol M, McDermott DF, et al：Survival, durabletumor remission, and long-term safety in patients withadvanced melanoma receiving nivolumab. J Clin Oncol 32：1020-1030, 201413）Taube JM, Klein A, Brahmer JR, et al：Association of PD-1,PD -1 ligands, and other features of the tumor immunemicroenvironment with response to anti-PD-1 therapy. ClinCancer Res 20：5064-5074, 2014 doi：10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.14）Lyford-Pike S, Peng S, Young GD, et al：Evidence for a roleof the PD-1：PD-L1 pathway in immune resistance of HPVassociatedhead and neck squamous cell carcinoma. CancerRes 73： 1733-1741, 2013